POST POLYCYTHEMIA VERA MYELOFIBROSIS
Clinical trials for POST POLYCYTHEMIA VERA MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new POST POLYCYTHEMIA VERA MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for POST POLYCYTHEMIA VERA MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for blood cancer patients: adding a second drug when the first one falters
Disease control TerminatedThis study tested whether adding a new drug called parsaclisib could help people with myelofibrosis, a serious bone marrow cancer, when their current treatment with ruxolitinib wasn't working well enough. About 177 participants who were already taking ruxolitinib but still had sy…
Matched conditions: POST POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug combo tested to fight rare blood cancer
Disease control TerminatedThis study tested whether adding a new drug called parsaclisib to an existing treatment (ruxolitinib) could better control myelofibrosis, a serious bone marrow cancer. It involved 252 adults with intermediate or high-risk disease who had not previously taken similar medications. …
Matched conditions: POST POLYCYTHEMIA VERA MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC